Minimally invasive glaucoma surgery (MIGS) refers to a group of surgical procedures aimed at treating glaucoma while minimizing trauma and promoting faster recovery compared to traditional glaucoma surgeries. These procedures are typically performed in combination with cataract surgery or as standalone interventions.
MIGS procedures are designed to lower intraocular pressure (IOP) by improving the outflow of aqueous humor, the fluid that circulates within the eye. By reducing IOP, MIGS can help slow down or halt the progression of glaucoma and preserve vision.
The Hydrus MicroStent by Alcon is a tiny device made of nitinol that is implanted in the eye at the time of cataract surgery. It is indicated in patients with mild to moderate primary open glaucoma.This device is one of the devices approved by the FDA under the category of MIGS procedures creating a ” trabecular meshwork bypass”. The Hydrus MicroStent generates a new pathway for aqueous humor to bypass the blocked or malfunctioning meshwork, enhancing drainage and decreasing the intraocular pressure.
It’s important to note that MIGS procedures are generally considered to be safer and less invasive than traditional glaucoma surgeries, such as trabeculectomy or tube shunt implants. They are often performed on patients with mild to moderate glaucoma, and the goal is to reduce the need for long-term medication use.
As with any surgical procedure, there are risks and potential complications associated with MIGS. It is essential to consult with an ophthalmologist or glaucoma specialist to determine the most suitable treatment approach based on individual circumstances and the specific type and severity of glaucoma.
https://www.myalcon.com/professional/cataract-surgery/hydrus-microstent/
